Single-Cell Transcriptomic Analysis Reveals Two Molecularly and Clinically Distinct Subtypes of Intrahepatic Cholangiocarcinoma

Guohe Song, Yang Shi, Lu Meng, Siyuan Huang, Jiaqiang Ma, Juan Zhang, Yang Yang, Jiaxin Li, Youpei Lin, Dongning Rao, Yifei Cheng, Jian Lin, Shuyi Ji, Yuming Liu, Shan Jiang, Xiaoliang Wang, Shu Zhang, Ai‐Wu Ke, Xiaoying Wang, Ya Cao, Yuan Ji, Jian Zhou, Jia Fan, Xiaoming Zhang, Ruibin Xi, Qiang GaoResearch 2021 · DOI

Intrahepatic cholangiocarcinoma (iCCA) is a highly aggressive and heterogeneous liver cancer. Despite its clinical significance, the biological diversity of iCCA has remained poorly understood, complicating efforts to develop effective personalized treatments. Traditionally, the World Health Organization (WHO) classifies iCCA into "large duct" and "small duct" types based on histology. However, this classification has lacked a deep molecular foundation to guide clinical decision-making.

In a landmark study published in Nature Communications, researchers utilized single-cell RNA sequencing (scRNA-seq) to map the cellular landscape of iCCA at unprecedented resolution. By analyzing 144,878 individual cells from 14 patients, the team identified two distinct molecular subtypes that correlate with clinical outcomes and unique immune microenvironments.

Mapping the Cellular Landscape

The researchers performed scRNA-seq on 14 pairs of iCCA tumors and adjacent non-tumor liver tissues. This approach allowed them to distinguish between malignant cells, immune cells, and stromal components with high precision.

Overview of the single-cell transcriptomic landscape and identification of two distinct iCCA subtypes.

As shown in the study workflow, the integration of scRNA-seq with whole-exome sequencing (WES) enabled the identification of malignant cells through copy number variation (CNV) analysis. The most striking finding was the discovery of two mutually exclusive markers: S100P and SPP1.

The S100P/SPP1 Binary: Defining Two Subtypes

The study reveals that iCCA can be divided into two primary molecular subtypes:

  1. $iCCA^{phl}$ (Perihilar Large Duct Type): Defined by the expression of S100P. These tumors are typically more aggressive, associated with higher levels of clinical markers like CA19-9 and CEA, and have a significantly worse prognosis.
  2. $iCCA^{pps}$ (Peripheral Small Duct Type): Defined by the expression of SPP1. These tumors are often associated with chronic liver diseases like cirrhosis and hepatitis B, but generally offer better overall survival for patients.

Validation across multiple independent cohorts, totaling over 400 patients, confirmed that $S100P^+$ patients had a significantly lower survival rate compared to $SPP1^+$ patients ($P = 0.008$).

CREB3L1: The Driver of Aggression

To understand why the $iCCA^{phl}$ subtype is more invasive, the researchers looked for master regulators using gene regulatory network analysis (SCENIC). They identified the transcription factor CREB3L1 as a key driver. CREB3L1, which is typically involved in endoplasmic reticulum (ER) stress responses, was found to directly regulate the expression of S100P. Functional assays demonstrated that knocking down CREB3L1 or S100P significantly reduced the ability of tumor cells to invade surrounding tissue, highlighting a potential therapeutic target for the more aggressive form of the disease.

"Cold" vs. "Hot" Immune Microenvironments

The study also highlights how these two subtypes exist in very different cellular "neighborhoods."

  • The $iCCA^{phl}$ environment is "immune-cold": It features significantly fewer infiltrating $CD3^+$ T cells and $CD56^+$ NK cells. Instead, it is enriched with $CCL18^+$ (M2-like) macrophages, which are known to suppress the immune response and promote tumor growth.
  • The $iCCA^{pps}$ environment is more active: It contains more $SPP1^+$ macrophages and shows a spectrum of cell differentiation. Interestingly, the researchers found cells ranging from hepatocyte-like ($ALB^+$) to stem-like ($ID3^+$). The presence of $ID3^+$ stem-like cells was associated with more extensive stroma (scar tissue) and a poorer prognosis within this specific subtype.

Clinical Implications and Future Directions

This high-resolution map provides a new framework for classifying iCCA that goes beyond simple histology. By identifying S100P and SPP1 as reliable markers, clinicians may eventually be able to better predict patient outcomes and tailor treatments. For instance, the study suggests that PSCA could be a potential immunotherapy target for the $iCCA^{phl}$ subtype.

While the discovery is promising, the authors note that further clinical trials are necessary to translate these molecular insights into bedside therapies. Understanding the specific interactions between tumor cells and their unique immune environments remains a critical frontier in the fight against this deadly cancer.

Summary updated

Abstract

Abstract Intrahepatic cholangiocarcinoma (iCCA) is a highly heterogeneous cancer with limited understanding of its classification and tumor microenvironment. Here, we performed single-cell RNA sequencing on 144,878 cells from 14 pairs of iCCA tumors and non-tumor liver tissues. We found that S100P and SPP1 are two reliable markers for iCCA perihilar large duct type (iCCA phl ) and peripheral small duct type (iCCA pps ). S100P + SPP1- iCCA phl has significantly reduced levels of infiltrating CD3 + T cells, CD56 + NK cells, and increased CCL18 + macrophages compared to S100P-SPP1 + iCCA pps . The transcriptor CREB3L1 is identified to regulate the S100P expression and promote tumor cell invasion. S100P-SPP1 + iCCA pps has significantly more SPP1 + macrophage infiltration, less aggressiveness and better survival than S100P + SPP1- iCCA phl . Moreover, S100P-SPP1 + iCCA pps harbors tumor cells at different status of differentiation, such as ALB + hepatocyte differentiation and ID3 + stemness. Our study extends our understanding of the diversity of tumor cells in iCCA and provides clearer understanding of iCCA classification.
BibTeX
@inproceedings{song2021single,
  author = {Guohe Song and Yang Shi and Lu Meng and Siyuan Huang and Jiaqiang Ma and Juan Zhang and Yang Yang and Jiaxin Li and Youpei Lin and Shuaixi Yang and Dongning Rao and Yifei Cheng and Jian Lin and Shuyi Ji and Yuming Liu and Shan Jiang and Xiaoliang Wang and Shu Zhang and Ai‐Wu Ke and Xiaoying Wang and Ya Cao and Yuan Ji and Jian Zhou and Jia Fan and Xiaoming Zhang and Ruibin Xi and Qiang Gao},
  title = {{Single-Cell Transcriptomic Analysis Reveals Two Molecularly and Clinically Distinct Subtypes of Intrahepatic Cholangiocarcinoma}},
  booktitle = {Research},
  year = {2021},
  doi = {10.21203/rs.3.rs-641386/v1},
}
Figure